Vedanta Biosciences to Present at the 2021 Jefferies Virtual Microbiome-Based Therapeutics Summit
April 15 2021 - 6:00AM
Business Wire
Vedanta Biosciences, a leading clinical-stage microbiome company
developing a new category of oral therapies using rationally
defined bacterial consortia manufactured from clonal cell banks,
today announced that Bernat Olle, PhD, Vedanta’s Chief Executive
Officer, will participate in the Executive Perspectives on Current
Challenges and Opportunities for Microbiome-Based Therapeutics
Panel and give a formal presentation at the 2021 Jefferies Virtual
Microbiome-Based Therapeutics Summit Thursday, April 22, 2021.
Event: 2021 Jefferies Virtual Microbiome-Based
Therapeutics Summit Date: Thursday, April 22, 2021 A
Pre-Recording of the Presentations will be made available on
Thursday, April 22, 2021 at 8:00 AM ET.
About Vedanta Biosciences
Vedanta Biosciences is leading the development of a potential
new category of oral therapies for immune-mediated diseases using
rationally defined bacterial consortia manufactured from clonal
cell banks. The Company’s approach bypasses the need to rely on
direct sourcing of donor fecal material of inconsistent
composition, thus overcoming challenges related to safety, quality,
and scalability that limit donor-derived approaches. The clinical
pipeline includes product candidates being evaluated for the
treatment of C. difficile infection, inflammatory bowel diseases,
advanced or metastatic cancers, and food allergy. These
investigational therapies are grounded in pioneering research –
published in leading journals including Science, Nature, and Cell –
that identified bacteria that induce a range of beneficial immune
responses. The Company’s platform includes what is believed to be
the largest library of bacteria derived from the human microbiome,
high throughput methods for bacterial consortium design, vast
datasets from human interventional studies, and state-of-the-art
capabilities for cGMP-compliant manufacturing of defined bacterial
consortia. Vedanta Biosciences controls a foundational intellectual
property portfolio covering compositions of matter and methods of
use for classes of bacteria that play key roles in human health.
Vedanta Biosciences was founded by PureTech Health (Nasdaq: PRTC,
LSE: PRTC) and a global team of scientific co-founders who
pioneered the modern understanding of how the immune system and the
microbiome cross-talk.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210415005182/en/
Investors and Media Chris Brinzey +1 617 835 9304
Chris.Brinzey@westwicke.com
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024